DelveInsight’s “High-grade Glioma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the High-grade Glioma, historical and forecasted epidemiology as well as the High-grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the High-grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; High-grade Glioma Market Forecast
Some of the key facts of the High-grade Glioma Market Report:
The High-grade Glioma market size was valued approximately USD 830 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In April 2025, Anova Enterprises, Inc. (Anova), a technology-driven contract research organization (CRO) focused on fast-tracking innovative therapies, has announced the enrollment of the first two participants in its much-anticipated clinical trial evaluating DB107 for brain tumors. This Phase 1/2a trial is a multicenter, open-label study aimed at assessing whether the addition of DB107 to the current standard-of-care (SOC) offers clinical benefit to patients with newly diagnosed high-grade gliomas (HGG), compared to outcomes from historical data.
In April 2025, The FDA has awarded Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100) for the treatment of pediatric-type diffuse high-grade gliomas (HGG). An upcoming Phase 1b dose-escalation trial (NCT06357377), which is not yet recruiting, will evaluate the safety, brain tumor penetration, and pharmacokinetics of NEO100 in patients diagnosed with pediatric-type diffuse HGG.
In April 2025, Preliminary findings from the Phase 2 IPAX-Linz study, as announced by Telix Pharmaceuticals Limited, show that treatment with TLX101 (¹³¹I-iodofalan1) demonstrated promising efficacy in patients with recurrent high-grade glioma, a form of brain cancer. The therapy was well tolerated, with no serious adverse events reported. Patients treated with TLX101 had a median overall survival of 12.4 months from the start of treatment and 32.2 months from their initial diagnosis.
In March 2025, Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotech company developing next-generation targeted antitumor virotherapies, together with City of Hope—one of the largest and most advanced cancer research and treatment centers in the U.S.—has announced promising progress from a Phase 1 clinical trial. The trial is evaluating Calidi’s investigational therapy CLD-101, a neural stem cell-based oncolytic virotherapy delivered directly into the brain. This marks the first study to assess the safety and therapeutic potential of a multi-dose regimen of this novel treatment in patients with recurrent high-grade glioma, one of the most aggressive and lethal brain cancers.
In the 7MM, the US had the largest market size for high-grade glioma, totaling nearly USD 580 million in 2023.
DCVax-L is anticipated to be the top revenue-generating therapy among all, with ONC-201 following closely in the 7MM by 2034.
In the 7MM, the US had the highest number of new high-grade glioma cases, totaling approximately 16,200 in 2023.
The incidence of glioblastoma significantly exceeds that of anaplastic astrocytoma. In the US in 2023, there were approximately 13,100 new cases of glioblastoma compared to around 1,600 cases of anaplastic astrocytoma.
Key High-grade Glioma Companies: Everfront Biotech Co., Ltd., BioMimetix JV, LLC, Chimerix, Laminar Pharmaceuticals, Nationwide Children’s Hospital, Rigel Pharmaceuticals, Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, and others
Key High-grade Glioma Therapies: Cerebraca wafer, BMX-001, ONC201, LAM561, Ribociclib, Olutasidenib + TMZ, Eflornithine + Lomustine, BMX-001, Regorafenib, Durvalumab (MEDI4736), Tasadenoturev (DNX-2401), ONC201, Berubicin, VBI-1901, Paxalisib (GDC-0084), AV-GBM-1, MDNA55, VAL-083 (Dianhydrogalactitol), Pomalidomide, LP561A1 (2-OHOA), ITI-1000 (pp65 DC Vaccine), INO-5401+ INO-9012+ Cemiplimab (REGN2810), and others
The High-grade Glioma epidemiology based on gender analyzed that High-grade Glioma is more common in men than in women
The High-grade Glioma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage High-grade Glioma pipeline products will significantly revolutionize the High-grade Glioma market dynamics.
High-grade Glioma Overview
High-grade glioma (HGG) refers to a group of aggressive brain tumors that arise from glial cells, which are supportive cells in the brain and spinal cord. These tumors are characterized by their rapid growth and tendency to invade surrounding brain tissue. High-grade gliomas are classified as grade III or grade IV tumors based on their histological features and aggressiveness.
Get a Free sample for the High-grade Glioma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/high-grade-glioma-hgg-market
High-grade Glioma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
High-grade Glioma Epidemiology Segmentation:
The High-grade Glioma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of High-grade Glioma
Prevalent Cases of High-grade Glioma by severity
Gender-specific Prevalence of High-grade Glioma
Diagnosed Cases of Episodic and Chronic High-grade Glioma
Download the report to understand which factors are driving High-grade Glioma epidemiology trends @ High-grade Glioma Epidemiology Forecast
High-grade Glioma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the High-grade Glioma market or expected to get launched during the study period. The analysis covers High-grade Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the High-grade Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
High-grade Glioma Therapies and Key Companies
Cerebraca wafer: Everfront Biotech Co., Ltd.
BMX-001: BioMimetix JV, LLC
ONC201: Chimerix
LAM561: Laminar Pharmaceuticals
Ribociclib: Nationwide Children’s Hospital
Olutasidenib + TMZ: Rigel Pharmaceuticals
Eflornithine + Lomustine: Orbus Therapeutics
BMX-001: BioMimetix
Regorafenib: Bayer
Durvalumab (MEDI4736): MedImmune
Tasadenoturev (DNX-2401): DNAtrix
Berubicin: CNS Pharmaceuticals
VBI-1901: VBI Vaccines
Paxalisib (GDC-0084): Kazia Therapeutics
AV-GBM-1: Aivita Biomedical
MDNA55: Medicenna Therapeutics
VAL-083 (Dianhydrogalactitol): DelMar Pharmaceuticals
Pomalidomide: Bristol-Myers Squibb
LP561A1 (2-OHOA): Laminar Pharmaceuticals
ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
INO-5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals
Discover more about therapies set to grab major High-grade Glioma market share @ High-grade Glioma Treatment Landscape
High-grade Glioma Market Strengths
Rise in HGG market is attributed to several factors such as aging population, evolving research, more diagnostic tests, developing surgical approaches, improved radio therapy techniques and novel systemic therapies.
Improvement in genomics and proteomics can lead to an acceleration in the discovery of novel treatment and drug deliverance.
High-grade Glioma Market Opportunities
Increasing incidence trend will provide better therapeutic approaches for the HGG market in the near future.
The market of High-grade Glioma is currently using Temozolomide and Evacizumab as approved therapies, but the market lacks an effective strategy to cure HGG, which provides a lucrative opportunity to develop more treatment options.
Scope of the High-grade Glioma Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
High-grade Glioma Therapeutic Assessment: High-grade Glioma current marketed and High-grade Glioma emerging therapies
High-grade Glioma Market Dynamics: High-grade Glioma market drivers and High-grade Glioma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
High-grade Glioma Unmet Needs, KOL’s views, Analyst’s views, High-grade Glioma Market Access and Reimbursement
To know more about High-grade Glioma companies working in the treatment market, visit @ High-grade Glioma Clinical Trials and Therapeutic Assessment
Table of Contents
1. High-grade Glioma Market Report Introduction
2. Executive Summary for High-grade Glioma
3. SWOT analysis of High-grade Glioma
4. High-grade Glioma Patient Share (%) Overview at a Glance
5. High-grade Glioma Market Overview at a Glance
6. High-grade Glioma Disease Background and Overview
7. High-grade Glioma Epidemiology and Patient Population
8. Country-Specific Patient Population of High-grade Glioma
9. High-grade Glioma Current Treatment and Medical Practices
10. High-grade Glioma Unmet Needs
11. High-grade Glioma Emerging Therapies
12. High-grade Glioma Market Outlook
13. Country-Wise High-grade Glioma Market Analysis (2020–2034)
14. High-grade Glioma Market Access and Reimbursement of Therapies
15. High-grade Glioma Market Drivers
16. High-grade Glioma Market Barriers
17. High-grade Glioma Appendix
18. High-grade Glioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
